WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. HIV drug resistance has been rarely reported among PrEP users who tested HIV positive in randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy

The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable results at the national, regional and global levels. This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years

EClinicalMedicine 1 (2018) 21–27 https://doi.org/10.1016/j.eclinm.2018.06.005 2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). EClinicalMedicine: journal homepage: https://www.journals.elsevier.com/ eclinicalmedicine Research Pape

HIV drug resistance , Users Manual December 2017

WHO Considering programmatic implications of rising levels of HIV drug resistance: finalizing the Global Action Plan Webinars 12 13 Dec 2016

12-13 December 2016 Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016